Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome.
Adult
Aged
Aged, 80 and over
Betacoronavirus
/ isolation & purification
Breast Neoplasms
/ pathology
COVID-19
Carcinoma, Ductal, Breast
/ pathology
Carcinoma, Lobular
/ pathology
Coronavirus Infections
/ epidemiology
Female
Follow-Up Studies
Humans
Italy
/ epidemiology
Mastectomy
/ statistics & numerical data
Middle Aged
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
Practice Patterns, Physicians'
/ standards
Prognosis
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
SARS-CoV-2
Covid-19 pandemic; elective breast cancer surgery;
Covid-19 protective cancer hubs
safety;
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
27 Aug 2020
27 Aug 2020
Historique:
received:
30
07
2020
accepted:
20
08
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
5
9
2020
Statut:
epublish
Résumé
The Covid-19 pandemic has challenged hard the national health systems worldwide. According to the national policy issued in March 2020 in response to the evolving Covid-19 pandemic, several hospitals were re-configured as Covid-19 centers and elective surgery procedures were rescheduled according to the most recent recommendations. In addition, Covid-19 protected cancer hubs were established, including the Regina Elena National Cancer Institute of Rome, Central Italy. At our Institute, the Breast Surgery Department continued working under the sign of a multidisciplinary approach. The number of professional figures involved in case evaluation was reduced to a minimum and interactions took place in the full respect of the required safety measures. Treatments for benign disease, pure prophylactic surgery and elective reconstructive procedures were all postponed and priority was assigned to the histologically-proven malignant breast tumors and highly suspicious lesions. From March 15th though April 30th 2020, we treated a total of 79 patients. This number is fully consistent with the average quantitative standards reached by our Department under ordinary circumstances. Patients were mostly discharged the day after surgery and none was readmitted due to surgery-related late complications. More generally, post-operative complications rates were unexpectedly low, particularly in light of the relatively high number of reconstructive procedures performed in this emergency situation. A strict follow up was performed based on the close contact with the surgical staff by telephone, messaging apps and telemedicine.Patients ascertainment for their Covid-19 status prior to hospital admission and hospital discharge allowed to maintain the "no-Covid-19" status at our Institution. In addition, during the aforementioned time window, none of the care providers developed SARS-CoV-2 infection or disease, as shown by the results of anti-SARS-CoV-2 immunoglobulin M and G profiling. In conclusions, elective breast cancer surgery procedures were successfully performed in a lockdown situation due to a novel viral pandemic. The well-coordinated regional and hospital efforts in terms of medical resource re-allocation and definition of clinical priorities allowed to maintain high quality standards of breast cancer care while ensuring safety to the cancer patients and care providers involved.
Identifiants
pubmed: 32854728
doi: 10.1186/s13046-020-01683-y
pii: 10.1186/s13046-020-01683-y
pmc: PMC7450921
doi:
Substances chimiques
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Références
JAMA. 2020 Mar 23;:
pubmed: 32203977
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
In Vivo. 2020 Jun;34(3 Suppl):1667-1673
pubmed: 32503827
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Ann Intern Med. 2020 Jun 3;:
pubmed: 32491919
Clin Breast Cancer. 2019 Apr;19(2):e358-e363
pubmed: 30691930